23andMe
2006
FOUNDED
PRIVATE
STATUS
601-700
EMPLOYEES
2ndary - Private
LATEST DEAL TYPE
45
INVESTORS
Description
Operator of a consumer genetics and research platform designed to help people access, understand and benefit from the human genome. The company's consumer genetics and research platform provides web-based interactive tools for individuals to learn and explore their own genetic information through DNA analysis technologies, enabling patients to gain deeper insights into personal ancestry, genealogy and inherited traits.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Primary Office
- 899 West Evelyn Avenue
- Mountain View, CA 94041
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore 23andMe’s full profile, request a free trial.
23andMe Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Secondary Transaction - Private | 01-May-2019 | 00000 | Completed | Generating Revenue | ||
| 15. Later Stage VC | 31-Mar-2019 | 00000 | Completed | Generating Revenue | ||
| 14. Later Stage VC | 27-Dec-2018 | 00000 | 00000 | 00.00 | Completed | Generating Revenue |
| 13. Secondary Transaction - Private | 03-Dec-2018 | 00000 | Completed | Generating Revenue | ||
| 12. Later Stage VC | 01-Jan-2018 | 00000 | Completed | Generating Revenue | ||
| 11. Secondary Transaction - Private | 22-Dec-2017 | 00000 | Completed | Generating Revenue | ||
| 10. Later Stage VC (Series F) | 12-Sep-2017 | 00000 | 00000 | 00.000 | Completed | Generating Revenue |
| 9. Later Stage VC | 00.000 | 00000 | Completed | Generating Revenue | ||
| 8. Grant | 13-Oct-2016 | $1.7M | $241M | Completed | Generating Revenue | |
| 7. Grant | 05-Apr-2016 | $250K | $241M | Completed | Generating Revenue |
23andMe Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series F1 | 00,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 000 |
| Series F | 00,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 00.00 |
| Series E | 00,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
| Series D | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series B | 9,048,560 | $0.000010 | $0.18 | $3.07 | $3.07 | 1x | $3.07 | 6.28% |
| Series A | 7,119,936 | $0.000010 | $0.08 | $1.26 | $1.26 | 1x | $1.26 | 4.94% |
23andMe Competitors (16)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorenson Genomics | Corporate Backed or Acquired | Salt Lake City, UT | 000000&0 | |||
| 0000000 00000000 | Venture Capital-Backed | San Diego, CA | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 000000 | Venture Capital-Backed | Palo Alto, CA | 000 | 00000 | 0000000000 0 | 00000 |
| 00000 00000000 | Private Equity-Backed | Aliso Viejo, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Tokyo, Japan | 0000 | 0000000000 0 | 0000 |
23andMe Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 | 13-Dec-2018 | 0000 00000 | 0000 | Social/Platform Software | |
| 000000 00 000000 | 20-Jul-2015 | 00000 00000 00 | 0000 | Other Healthcare Services | 0000 00000000 |
| CureTogether | 10-Jul-2012 | Merger/Acquisition | Decision/Risk Analysis | 0000 00000000 |
23andMe Investors (45)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Next Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Hendale Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | ||
| Hercules Capital | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | ||
| Quantum Global Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| GlaxoSmithKline | Corporation | Minority | 000 0000 | 000000 0 |
23andMe Executive Team (39)
25 Former Executives
You’re viewing 5 of 39 executives. Get the full list »23andMe Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anne Wojcicki | 23andMe | Co-Founder, Chief Executive Officer & Board Member | 000 0000 | |
| Esther Dyson | Self | Board Member | 000 0000 | |
| Neal Mohan | 23andMe | Board Member | 000 0000 | |
| Roelof Botha | Sequoia Capital | Board Member | 000 0000 |
3 Former Board Members
You’re viewing 4 of 7 board members. Get the full list »